



Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 31, 2023 12:30 PM EDT

WILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) -- [Prelude Therapeutics Incorporated](#) (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference, taking place in New York City, June 7 to 9, 2023.

Details are as follows:

On Wednesday, **June 7th, at 8:00 a.m. ET, Kris Vaddi, Ph.D., CEO of Prelude will participate in a fireside chat.** The live webcast is available [here](#) and will be available for replay for 90 days.

Dr. Vaddi, joined by **Jane Huang, MD, President and Chief Medical Officer** and **Laurent Chardonnet, Chief Financial Officer**, will host one-on-one meetings on June 7th.

About Prelude

Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude's diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor; PRT3645, a brain penetrant CDK4/6 inhibitor; and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

For more information, visit our [website](#) and follow us on [LinkedIn](#) and [Twitter](#).

Investor Contact:

Lindsey Trickett
Vice President, Investor Relations
240.543.7970
ltrickett@preludetx.com

Media Contact:

Helen Shik
Shik Communications
617.510.4373
Helen@ShikCommunications.com